The data show that "these groundbreaking medications are poised to revolutionize cardiovascular care and could dramatically enhance cardiovascular health," said Dr
Barcelona, Spain: FEBSF, 1996 Di Marzio L, Moretti S, DAlo S, et al
Dapagliflozin demonstrated superiority over placebo in improving HF-related outcomes, reducing the composite endpoint of worsening HF or cardiovascular death, lowering HF hospitalization rates, and alleviating symptom burden
6 There is also no evidence yet for long-term sustainable weight loss with GLP-1RA after the first one to two years, 5 with the STEP-4 trial showing that patients unfortunately regain weight quickly when discontinuing semaglutide injection
Whilst Rybelsus itself is not associated with increased clotting risk, patients with type 2 diabetes should remain vigilant for signs and symptoms of thromboembolism due to their underlying condition
M13, frankincense ( Boswellia carterii serrata )